Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

I and SPIRIT III trials demonstrated the following key results for XIENCE V at two years:

-- A clinically significant 31 percent reduction in the risk of ischemia-driven Target Vessel Failure (TVF, cardiac events related to the treated vessel) compared to TAXUS (10.4 percent for XIENCE V vs. 14.7 percent for TAXUS, p-value=0.03)*. TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

-- A clinically significant 45 percent reduction in the risk of ischemia-driven major adverse cardiac events (MACE) compared to TAXUS (7.1 percent for XIENCE V vs. 12.3 percent for TAXUS, p-value=0.001). MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (TLR driven by lack of blood supply).

-- An observed 28 percent reduction in the risk of all-cause death compared to TAXUS (2.4 percent for XIENCE V vs. 3.3 percent for TAXUS, p-value=0.36)*.

-- An observed 28 percent reduction in the risk of cardiac death compared to TAXUS (0.9 percent for XIENCE V vs. 1.3 percent for TAXUS, p-value=0.56)*.

-- A clinically significant 45 percent reduction in the risk of heart attack (MI) compared to TAXUS (3.1 percent for XIENCE V vs. 5.6 percent for TAXUS, p-value=0.03)*.

-- A clinically significant 39 percent reduction in the risk of all-cause death or heart attack (MI) compared to TAXUS (5.1 percent for XIENCE V vs. 8.3 percent for TAXUS, p-value=0.03)*.

-- A clinically significant 41 percent reduction in the risk of cardiac death or heart attack (MI) compared to TAXUS (3.8 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.04)*.

-- A clinically significant 41 percent reduction in the risk of ischemia-driven target lesion revascularization (ID-TLR) compa
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015  Xcelience, a contract development ... has made a structured cash investment in Powdersize, ... in milling, micronization and powder size classification within ... Powdersize,s business while simultaneously adding a complete set ... of capabilities. "As we continue ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Calif., Feb.16, 2012   HealthWarehouse.com , Inc. (OTC: HEWA), ... MedLion , Inc., a pioneering direct primary care ... and uninsured people in the Bay Area, Central Coast ... their homes. Nearly seven million Californians lacked ...
... KING OF PRUSSIA, Pa., Feb. 16, 2012 Medical ... the first fully-monitored medical alarm system that allows the ... today provides investors with an update on current initiatives. ... Inc. CFO and President, Ronald Adams. "We ...
Cached Medicine Technology:HealthWarehouse.com Partners With MedLion to Bring Affordable Healthcare to Northern California 2HealthWarehouse.com Partners With MedLion to Bring Affordable Healthcare to Northern California 3Medical Alarm Concepts Investor Update -- News on Current Initiatives 2Medical Alarm Concepts Investor Update -- News on Current Initiatives 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... What are the STASH awards? The Significant Technological Achievements in Secretive Horticulture ... community as well as tried-and-true products that have stood the test of time. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for authentic ... at Grant Park. The festival will end on Sunday, August 2nd. ... the annual Lollapalooza. This unique and unbelievably popular festival attracts the best in ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source ... launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and ... Prep from MDLinx makes preparing for the exam easy and painless. MDLinx offers ...
(Date:7/31/2015)... (PRWEB) , ... July 31, ... ... Jason T. Brown’s live lecture on pharmaceutical negligence is now available online ... was well received with a 94% approval rating from the nationwide audience. ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... , ST. LOUIS, Nov. 20 Centene ... will present at the Bank of America Merrill Lynch 2009 ... Crowne Plaza Hotel Times Square in New York City. , ... Time. Investors and other interested parties may access a live, ...
... Nov. 20 Samuel Gladding is no Scrooge, but he ... be "happy" during the holidays. As a licensed professional counselor ... Department of Counseling at Wake Forest University, Gladding says research ... often leads to sadness and even depression during the holidays. ...
... , , NEW YORK, Nov. ... announced that it will broadcast Doctor Radio Reports: What ... by veteran journalist Perri Peltz. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) , ... About Mammograms will air November 21 live at 10:00 ...
... durations of exposure to formaldehyde used for embalming in ... of death from myeloid leukemia, according to a new ... of the National Cancer Institute . Previous studies ... cancer in anatomists, pathologists, and funeral industry workers, all ...
... Washington) November 20, 2009Emergency medical service (EMS) providers ... cardiac arrests each year. Only 5 to ... arrest survive. Better quality cardiopulmonary resuscitation (CPR) ... with better patient outcome. The Resuscitation Outcomes ...
... short as 34 weeks, potentially adding to preemie delivery rate, experts ... that the rate of preterm deliveries continues to climb in the ... Many women are confused about what constitutes a full-term birth in ... the study considered a baby born at 34 to 36 weeks ...
Cached Medicine News:Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
Medicine Products: